Phase 2 Long COVID Trial, Recruiting NCT06940609 Sponsor: University of New Mexico Condition: Long COVID
Back to Long Covid

Phase 2 Long COVID Trial, Recruiting

NCT06940609
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old
  • You have been formally diagnosed with Long COVID (also called Post-Acute Sequelae of COVID, or PASC) and still have ongoing symptoms, confirmed by a specific symptom checklist score (confirm with trial site)
  • One of your ongoing symptoms is "brain fog" or difficulty thinking clearly
  • You are fluent in English
  • If you take any medications for mental health or mood, your dose has stayed the same for at least the past month

Who may not be able to join:

  • You have a history of a neurological condition (such as epilepsy or seizures) or any other neurological disease
  • You have a history of a psychotic disorder, such as schizophrenia or bipolar disorder
  • You currently have an ongoing problem with alcohol or drug dependence
  • You have an implanted electrical device in your body, such as a pacemaker
  • You were hospitalised for a medical reason within the past four weeks
  • You have any condition that would stop you from completing the full study
  • You have a legally appointed representative making decisions on your behalf
  • You are currently involved in any legal case related to a medical diagnosis or disability claim
  • You have any reason you cannot safely have an MRI scan
  • You are under 18, currently pregnant, or currently in prison

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Davin Quinn, MD, University of New Mexico

Phone: 505-272-9552

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of New Mexico
Registry
ClinicalTrials.gov
Start date
7 July 2025
Est. completion
30 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Aim 1; Aim 2

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov